Peripheral biomarkers in Repeated Ketamine Infusions Trial
Amanda van Geel
Study at a glance
AI-extracted from the abstract| Characteristics | Clinical trial |
|---|---|
| Population | Patients with Major Depressive Disorder |
| Intervention | Ketamine |
| Topics | Depression Ketamine Esketamine |
| Keywords | Antidepressant Endocrine system Peripheral Depression economics Clinical trial Glucocorticoid Immune system Anesthesia Immunology Hormone |
| Key findings | Repeated ketamine treatment reduced depressive symptoms and suicidal ideation but did not significantly alter plasma CRP levels, and affected morning salivary cortisol in a sex-dependent way. |
Abstract
Abnormalities in the endocrine and immune systems are well documented in patients with Major Depressive Disorder (MDD), however, the mechanisms by which the novel antidepressant treatment, ketamine, influences these physiological systems are unclear. This study examined the effects of repeated ketamine infusions on the endocrine and immune systems using the peripheral biomarkers C-reactive protein (CRP) and cortisol. While both depressive symptoms and suicidal ideation were reduced with repeated ketamine treatment, there was no significant change in plasma CRP levels throughout the clinical trial. Morning salivary cortisol did change throughout the clinical trial in a sex-dependent way. Further sex-specific investigation into ketamine's effect on glucocorticoid expression is needed to advance the knowledge of the underlying mechanisms of ketamine's rapid antidepressant effects to more effectively treat patients with depression.
Comparable studies
Other non-randomized and open-label trials on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder | 2010 | Open-label trial | n = 33 |
| Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression Adults (≥ 18 years) with treatment-resistant depression | 2020 | Phase 3, open-label, multicenter, long-term study | n = 802 |
| Intravenous arketamine for treatment-resistant depression: open-label pilot study Humans with treatment-resistant depression | 2020 | Open-label pilot trial | n = 7 |
| A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide. Hospitalized patients with Major Depressive Disorder and acute suicidal ideation and... | 2024 | Open label study | n = 17 |
| Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression Participants with DSM-IV-defined major depressive disorder and treatment-resistant... | 2014 | Pooled analysis of three clinical trials | n = 97 |
Citations in the library
Cites 45
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
and 40 more in the library